155 related articles for article (PubMed ID: 21124075)
1. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
[TBL] [Abstract][Full Text] [Related]
2. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
[TBL] [Abstract][Full Text] [Related]
3. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
Bhat R; Dempe S; Dinsart C; Rommelaere J
Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
[TBL] [Abstract][Full Text] [Related]
5. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
Bhat R; Rommelaere J
BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
[TBL] [Abstract][Full Text] [Related]
6. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
[TBL] [Abstract][Full Text] [Related]
7. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract][Full Text] [Related]
8. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
Viruses; 2021 May; 13(6):. PubMed ID: 34071585
[TBL] [Abstract][Full Text] [Related]
9. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
Dempe S; Lavie M; Struyf S; Bhat R; Verbeke H; Paschek S; Berghmans N; Geibig R; Rommelaere J; Van Damme J; Dinsart C
Cancer Immunol Immunother; 2012 Nov; 61(11):2113-23. PubMed ID: 22576056
[TBL] [Abstract][Full Text] [Related]
10. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
[TBL] [Abstract][Full Text] [Related]
11. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
13. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
[TBL] [Abstract][Full Text] [Related]
14. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
[TBL] [Abstract][Full Text] [Related]
15. Double-faceted mechanism of parvoviral oncosuppression.
Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
17. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
[TBL] [Abstract][Full Text] [Related]
18. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
Akladios C; Aprahamian M
Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
[TBL] [Abstract][Full Text] [Related]
19. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity.
Raykov Z; Grekova S; Leuchs B; Aprahamian M; Rommelaere J
Int J Cancer; 2008 Jun; 122(12):2880-4. PubMed ID: 18360875
[TBL] [Abstract][Full Text] [Related]
20. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]